Authors
Latest:
Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 TrialJessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.
Latest:
Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in MyelomaPaul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.
Latest:
Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AMLJessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).
Latest:
Emerging Combinations for FLT3-Mutated AMLJessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.
Latest:
Dr. Berger on Chemotherapy Delivery Options in Ovarian CancerJessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.
Latest:
Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPCFebruary 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.
Latest:
Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple MyelomaJesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.
Latest:
Dr Berdeja on the Evolving Use of CAR T-Cell Therapy in Multiple MyelomaJesus Berdeja, MD, director, discusses the evolving guidelines regarding the use of CAR T-cell therapy in patients with multiple myeloma.
Latest:
Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple MyelomaJesus San Miguel, MD, PhD, professor of Hematology, medical director of the ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Ruan on the Future of Lenalidomide/Rituximab in MCLJia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.
Latest:
Enhancing Immune System May Boost Survival for Brain Cancer PatientsResearchers at Washington University in St. Louis and elsewhere are focusing on lymphocytes, the essential effector cells in the immune response to cancer.
Latest:
Dr. Rao on Testing for Somatic and Germline MutationsJianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.
Latest:
Dr. Niu on Treatment Updates in RET+/KRAS+ NSCLCJason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.
Latest:
Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCCJihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).
Latest:
The Importance of Curiosity in Expanding Cancer ImmunologyJill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.
Latest:
Nab-Paclitaxel Boosts Survival in Pancreatic CancerThe addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.
Latest:
Dr. Hu on the Increase in Incidence of Advanced Prostate CancerJim C. Hu, MD, professor of Urology, Weill Cornell Medical College, discusses the increase in the incidence of advanced prostate cancer in the United States.
Latest:
Jim Feldman on the Importance of Social Networking for UrologistsJim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.
Latest:
Dr. Hu on Active Surveillance for Prostate CancerJim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.
Latest:
Explaining the Variability of Biologics and BiosimilarsJim M. Koeller, MS, FHOPA, discusses the inherent variability of recombinant DNA technology behind biosimilars.
Latest:
Impact of Trilaciclib on the Treatment LandscapeRalph Boccia, MD, and Jim Schwartz, RPh, discuss the overall impact the approval for trilaciclib will have on patients’ treatment outcomes, health care expenses, and quality of life.
Latest:
Dr. Holland on the Stigma Toward Psychosocial CareDr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Ai on the Use of Hypomethylating Agents in Patients With MDSJing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Dr. Hou on Polatuzumab Vedotin in DLBCLJing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Zhang on the State of Risk Stratification in mCRPCJingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.
Latest:
Opportunities and Challenges: A Time to Reflect at the End of a Busy YearIt is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.
Latest:
Dr. Zujewski Discusses Breast Cancer Drug DevelopmentJo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.
